Integrated Biosciences Joins Illumina Ventures Labs to Design Novel Therapeutics Targeting the Transcriptome
Integrated Biosciences has joined Illumina Ventures Labs to accelerate the development of novel therapeutics targeting the transcriptome.
This partnership merges Integrated Biosciences' AI/ML-enabled drug discovery with Illumina's sequencing technologies.
The collaboration aims to discover small molecule therapeutics for age-related diseases by altering RNA expression and DNA modifications.
Felix Wong, Ph.D., co-founder of Integrated Biosciences, states that the partnership will generate large-scale datasets to map and alter cell states, targeting age-related diseases.
Ron Mazumder, Ph.D., Partner at Illumina Ventures, emphasizes the investment's potential to unlock new therapeutic candidates and modalities.
- Partnership enhances Integrated Biosciences' drug discovery using Illumina's sequencing technology.
- Integration of AI/ML capabilities with sequencing aimed at creating novel small molecule therapeutics.
- Focus on age-related diseases, a growing market segment.
- Support from Illumina Ventures Labs includes both monetary and scientific resources.
- Potential to generate large-scale datasets for mapping cell states and targeting diseases.
- Previous successes include the discovery of a novel class of antibiotics, showcasing proven capabilities.
- Reliance on successful integration of AI/ML and sequencing technologies.
- Preclinical stage assets mean a long timeline before potential market introduction.
- High dependency on the partnership's continued support and resources.
- Risk of failure in drug discovery processes despite advanced technology.
Insights
The partnership between Integrated Biosciences and Illumina Ventures Labs marks a significant advancement in the field of drug discovery. By combining Integrated Biosciences' expertise in AI/ML-enabled small molecule drug discovery with Illumina's cutting-edge sequencing technology, the collaboration is poised to create a unique synergy that could accelerate the development of novel therapeutics.
One of the key benefits is the creation of large-scale datasets that map cell states and how they can be altered. This data will be invaluable in the pursuit of precision medicine, allowing for more targeted treatments with potentially fewer side effects. The focus on transcriptomes and methylomes—which are important for understanding gene expression and regulation—provides a promising avenue for tackling age-related diseases, a growing concern in an aging population.
However, the partnership is still in its early stages and it remains to be seen how quickly and effectively these innovations can be translated into clinical applications. Despite this, the collaboration's track record and the scientific support from Illumina Ventures offer promising signs for future breakthroughs.
From a financial perspective, the alliance provides
Investors should note Integrated Biosciences' previous successes, such as the discovery of novel antibiotics, which lend credibility to their innovative capabilities. However, as with any early-stage biotechnology firm, there is inherent risk involved. The full financial impact will largely depend on the successful development and commercialization of these new drug candidates.
In the short term, this partnership could lead to increased spending on R&D, which might affect profitability. On the other hand, the long-term potential for revenue generation through successful drug discovery could be substantial, making this a high-risk but potentially high-reward investment.
Partnership combines Integrated Biosciences’ pioneering research in AI/ML-enabled small molecule drug discovery and bulk and single cell sequencing offered through Illumina Ventures Labs
“All drugs act by modifying cellular components, and nucleic acids are particularly important. This partnership is a nexus to using small molecules to systematically target RNA expression and DNA modifications across cell types, such that we can control exactly how cells behave,” said Felix Wong, Ph.D. co-founder of Integrated Biosciences. “We will generate unprecedented large-scale datasets that provide maps of cell states and how to alter them, charting the course for definitive cures for age-related diseases.”
“Illumina Ventures supports innovative companies that are pursuing breakthrough science, and our partnership with Integrated Biosciences, through our Illumina Ventures Labs, represents an investment in the intersection of healthcare, genomics, and sequencing,” said Ron Mazumder, Ph.D., Partner at Illumina Ventures. “Integrated Biosciences is an outlier early-stage company that has already pioneered breakthroughs in drug discovery. Illumina Ventures is convinced that, with our unique support and resources, Integrated Biosciences will unlock novel therapeutic candidates and modalities that bring next-generation sequencing to the forefront of drug discovery.”
Integrated Biosciences has previously published its drug discovery engine in leading journals, including Nature, Nature Aging, and Cell Systems. The company is currently developing a portfolio of preclinical-stage assets to treat multiple age-related diseases. The partnership with Illumina Ventures will generate additional therapeutic assets and new discovery platforms that hold the promise of reshaping drug discovery. Integrated Biosciences has a proven track record of doing so, having previously reported in the journal Nature on the discovery of one of the first novel structural classes of antibiotics in over 60 years.
About Integrated Biosciences
Integrated Biosciences is a biotechnology company pioneering synthetic biology and AI-driven small-molecule drug discovery to produce next-generation therapeutics targeting age-related diseases. The company was founded by MIT-, Harvard- and
About Illumina Ventures Labs
Illumina Ventures Labs provides a unique advantage to accelerate value creation for genomics start-ups, from company formation to Series A financings, via access to capital, sequencing, mentorship, and fully equipped genomics lab capabilities. Illumina Ventures Labs is affiliated with Illumina Ventures, an independently managed, healthcare-focused venture firm in a strategic partnership with Illumina (NASDAQ: ILMN). As an early-stage, value-add investor, Illumina Ventures helps entrepreneurs develop breakthrough science and technologies into market-leading companies to transform healthcare. For more information, visit illuminaventures.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240528038759/en/
Anthony Petrucci
Bioscribe
512-581-5442
anthony@bioscribe.com
Source: Integrated Biosciences
FAQ
What is the focus of the partnership between Integrated Biosciences and Illumina Ventures Labs?
How will Integrated Biosciences benefit from the Illumina Ventures Labs partnership?
What diseases are targeted by the new therapeutics developed through the partnership?
What is the significance of the partnership for Integrated Biosciences?
What previous successes has Integrated Biosciences achieved in drug discovery?
